Bid chimeras indicate that most BH3-only proteins can directly activate Bak and Bax, and show no preference for Bak versus Bax

Cell Death and Disease

Volumn 6, Issue 4, 2015, Pages

  Hockings, C ^a,b   Anwari, K ^a,b   Ninnis, R L ^a,b   Brouwer, J ^a,b   O'Hely, M ^a,b   Evangelista, M ^a,b   Hinds, M G ^c,d   Czabotar, P E ^a,b   Lee, E F ^a,b   Fairlie, W D ^a,b   Dewson, G ^a,b   Kluck, R M ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d LA TROBE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; PROTEIN; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL XL; PROTEIN BID; PROTEIN BIK; PROTEIN HRK; PROTEIN MCL 1; PROTEIN NOXA; PUMA PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; BAK1 PROTEIN, HUMAN; BAX PROTEIN (53-86); BAX PROTEIN, HUMAN; BID PROTEIN, HUMAN; C22ORF29 PROTEIN, HUMAN; ONCOPROTEIN; PEPTIDE FRAGMENT; PROTEIN BCL 2; PROTEIN BCL X;

AMINO ACID SEQUENCE; ARTICLE; CHIMERA; CONTROLLED STUDY; HUMAN; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PURIFICATION; PROTEIN TARGETING; ANIMAL; APOPTOSIS; C57BL MOUSE; DRUG EFFECTS; ENZYME SPECIFICITY; GENETICS; KNOCKOUT MOUSE; METABOLISM; MITOCHONDRIAL MEMBRANE; MOLECULAR GENETICS; MOUSE; PHYSIOLOGY;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOCHONDRIA; MITOCHONDRIAL MEMBRANES; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, FUSION; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SUBSTRATE SPECIFICITY;

EID: 84989832275     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.105     Document Type: Article

References (58)

1. Youle RJ, Strasser A. The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
2. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15: 49-63.
3. Shamas-Din A, Kale J, Leber B, Andrews DW. Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb Perspect Biol 2013; 5: A008714.
4. Happo L, Strasser A, Cory S. BH3-only proteins in apoptosis at a glance. J Cell Sci 2012; 125: 1081-1087.
5. Letai AG, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002; 2: 183-192.
6. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403.
7. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294-1305.
8. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005; 17: 525-535.
9. Kim H, Rafiuddin-Shah M, Tu H-C, Jeffers JR, Zambetti GP, Hsieh JJ et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 2006; 8: 1348-1358.
10. Fletcher JI, Meusburger S, Hawkins CJ, Riglar DT, Lee EF, Fairlie WD et al. Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proc Natl Acad Sci USA 2008; 105: 18081-18087.
11. Llambi F, Moldoveanu T, Tait SWG, Bouchier-Hayes L, Temirov J, McCormick LL et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell 2011; 44: 517-531.
12. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-3428.
13. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202-208.
14. Hinds MG, Smits C, Fredericks-Short R, Risk JM, Bailey M, Huang DCS et al. Bim, Bad and Bmf: Intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets. Cell Death Differ 2007; 14: 128-136.
15. Barrera-Vilarmau S, Obregón P, de Alba E. Intrinsic order and disorder in the bcl-2 member harakiri: Insights into its proapoptotic activity. PLoS One 2011; 6: E21413.
16. Peng Z, Xue B, Kurgan L, Uversky VN. Resilience of death: Intrinsic disorder in proteins involved in the programmed cell death. Cell Death Differ 2013; 20: 1257-1267.
17. Wilfling F, Weber A, Potthoff S, Vögtle F-N, Meisinger C, Paschen SA et al. BH3-only proteins are tail-anchored in the outer mitochondrial membrane and can initiate the activation of Bax. Cell Death Differ 2012; 19: 1328-1336.
18. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315: 856-859.
19. Billen LP, Kokoski CL, Lovell JF, Leber B, Andrews DW. Bcl-XL inhibits membrane permeabilization by competing with Bax. PLoS Biol 2008; 6: E147.
20. Dai H, Smith A, Meng XW, Schneider PA, Pang YP, Kaufmann SH. Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. J Cell Biol 2011; 194: 39-48.
21. Ren D, Tu H-C, Kim H, Wang GX, Bean GR, Takeuchi O et al. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science 2010; 330: 1390-1393.
22. Villunger A, Labi V, Bouillet P, Adams JM, Strasser A. Can the analysis of BH3-only protein knockout mice clarify the issue of 'direct versus indirect' activation of Bax and Bak? Cell Death Differ 2011; 18: 1545-1546.
23. Du H, Wolf J, Schafer B, Moldoveanu T, Chipuk JE, Kuwana T. BH3 domains other than Bim and Bid can directly activate Bax/Bak. J Biol Chem 2011; 286: 491-501.
24. Czabotar PE, Westphal D, Dewson G, Ma S, Hockings C, Fairlie WD et al. Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell 2013; 152: 519-531.
25. Sarosiek KA, Chi X, Bachman JA, Sims JJ, Montero J, Patel L et al. BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Mol Cell 2013; 51: 751-765.
26. Cartron P-FF, Gallenne T, Bougras G, Gautier F, Manero F, Vusio P et al. The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. Mol Cell 2004; 16: 807-818.
27. Dai H, Pang YP, Ramirez-Alvarado M, Kaufmann SH. Evaluation of the BH3-only protein Puma as a direct Bak activator. J Biol Chem 2014; 289: 89-99.
28. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer SJ, Armstrong SA et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351-365.
29. Merino D, Giam M, Hughes PD, Siggs OM, Heger K, O'Reilly LA et al. The role of BH3-only protein Bim extends beyond inhibiting Bcl-2-like prosurvival proteins. J Cell Biol 2009; 186: 355-362.
30. Ahsen von O, Renken C, Perkins G, Kluck RM, Bossy-Wetzel E, Newmeyer DD. Preservation of mitochondrial structure and function after Bid- or Bax-mediated cytochrome c release. J Cell Biol 2000; 150: 1027-1036.
31. Sattler M, Liang H, Nettesheim DG, Meadows RP, Harlan JE, Eberstadt M et al. Structure of Bcl-xL-Bak peptide complex: Recognition between regulators of apoptosis. Science 1997; 275: 983-986.
32. Chou JJ, Li H, Salvesen GS, Yuan J, Wagner G. Solution structure of BID, an intracellular amplifier of apoptotic signaling. Cell 1999; 96: 615-624.
33. Lovell JF, Billen LP, Bindner S, Shamas-Din A, Fradin C, Leber B et al. Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell 2008; 135: 1074-1084.
34. García-Sáez AJ, Ries J, Orzáez M, Pérez-Payá E, Schwille P. Membrane promotes tBID interaction with BCL(XL). Nat Struct Mol Biol 2009; 16: 1178-1185.
35. Bleicken S, García-Sáez AJ, Conte E, Bordignon E. Dynamic interaction of cBid with detergents, liposomes and mitochondria. PLoS One 2012; 7: E35910.
36. Zha J, Weiler S, Oh KJ, Wei MC, Korsmeyer SJ. Posttranslational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis. Science 2000; 290: 1761-1765.
37. Walensky LD, Pitter K, Morash J, Oh KJ, Barbuto S, Fisher JK et al. A stapled BID BH3 helix directly binds and activates BAX. Mol Cell 2006; 24: 199-210.
38. Renault TT, Floros KV, Chipuk JE. BAK/BAX activation and cytochrome c release assays using isolated mitochondria. Methods 2013; 61: 146-155.
39. Moldoveanu T, Grace CR, Llambi F, Nourse A, Fitzgerald P, Gehring K et al. BID-induced structural changes in BAK promote apoptosis. Nat Struct Mol Biol 2013; 20: 589-597.
40. Uren RT, Dewson G, Chen L, Coyne SC, Huang DCS, Adams JM et al. Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak. J Cell Biol 2007; 177: 277-287.
41. Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M et al. tBID, a membranetargeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev 2000; 14: 2060-2071.
42. Ruffolo SC, Shore GC. BCL-2 selectively interacts with the BID-induced open conformer of BAK, inhibiting BAK auto-oligomerization. J Biol Chem 2003; 278: 25039-25045.
43. Oh KJ, Barbuto S, Pitter K, Morash J, Walensky LD, Korsmeyer SJ. A membrane-targeted BID BCL-2 homology 3 peptide is sufficient for high potency activation of BAX in vitro. J Biol Chem 2006; 281: 36999-37008.
44. Oh KJ, Singh P, Lee K, Foss K, Lee S, Park M et al. Conformational changes in BAK, a poreforming proapoptotic Bcl-2 family member, upon membrane insertion and direct evidence for the existence of BH3-BH3 contact interface in BAK homo-oligomers. J Biol Chem 2010; 285: 28924-28937.
45. Terrones O, Etxebarria A, Landajuela A, Landeta O, Antonsson B, Basañez G. BIM and tBID are not mechanistically equivalent when assisting BAX to permeabilize bilayer membranes. J Biol Chem 2008; 283: 7790-7803.
46. Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004; 305: 1466-1470.
47. Rogers JM, Oleinikovas V, Shammas SL, Wong CT, De Sancho D, Baker CM et al. Interplay between partner and ligand facilitates the folding and binding of an intrinsically disordered protein. Proc Natl Acad Sci USA 2014; 111: 15420-15425.
48. Gong X-M, Choi J, Franzin CM, Zhai D, Reed JC, Marassi FM. Conformation of membraneassociated proapoptotic tBid. J Biol Chem 2004; 279: 28954-28960.
49. Yao Y, Bobkov AA, Plesniak LA, Marassi FM. Mapping the interaction of pro-apoptotic tBID with pro-survival BCL-XL. Biochemistry 2009; 48: 8704-8711.
50. Rautureau GJP, Day CL, Hinds MG. Intrinsically disordered proteins in bcl-2 regulated apoptosis. Int J Mol Sci 2010; 11: 1808-1824.
51. Wang Y, Tjandra N. Structural insights of tBid, the caspase-8-activated Bid, and its BH3 domain. J Biol Chem 2013; 288: 35840-35851.
52. Brouwer JM, Westphal D, Dewson G, Robin AY, Uren RT, Bartolo R et al. Bak core and latch domains separate during activation, and freed core domains form symmetric homodimers. Mol Cell 2014; 55: 938-946.
53. Uren RT, Dewson G, Bonzon C, Lithgow T, Newmeyer DD, Kluck RM. Mitochondrial release of pro-apoptotic proteins: Electrostatic interactions can hold cytochrome c but not Smac/ DIABLO to mitochondrial membranes. J Biol Chem 2005; 280: 2266-2274.
54. Tran VH, Bartolo R, Westphal D, Alsop A, Dewson G, Kluck RM. Bak apoptotic function is not directly regulated by phosphorylation. Cell Death Dis 2013; 4: E452.
55. Lee EF, Czabotar PE, van Delft MF, Michalak EM, Boyle MJ, Willis SN et al. A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. J Cell Biol 2008; 180: 341-355.
56. Pezzella F, Tse AG, Cordell JL, Pulford KA, Gatter KC, Mason DY. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 1990; 137: 225-232.
57. Dewson G, Kratina T, Sim HW, Puthalakath H, Adams JM, Colman PM et al. To trigger apoptosis, Bak exposes its BH3 domain and homodimerizes via BH3: Groove interactions. Mol Cell 2008; 30: 369-380.
58. Banerjee A, Grumont R, Gugasyan R, White C, Strasser A, Gerondakis S. NF-kappaB1 and c-Rel cooperate to promote the survival of TLR4-activated B cells by neutralizing Bim via distinct mechanisms. Blood 2008; 112: 5063-5073.